Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
N
Nxera Pharma Co Ltd
OTC:SOLTF
Nxera Pharma Co Ltd
OTC:SOLTF
Price:
7.815
USD
Market Cap:
$702.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Nxera Pharma Co Ltd
OTC:SOLTF
|
JP |
|
H
|
Hwa Fong Rubber Thailand PCL
SET:HFT
|
TH |
|
Actinium Pharmaceuticals Inc
F:7AY1
|
US |
|
P
|
Pharmadrug Inc
CNSX:PHRX
|
CA |
|
J
|
Jasmine Technology Solution PCL
SET:JTS
|
TH |
Wall St Price Targets
SOLTF Price Forecast
Based on 10 analysts
Based on 10 analysts
+60% Upside
from
$7.815
today
Nxera Pharma Co Ltd (SOLTF)’s 12-month stock price forecast through October 2027 has a consensus target of $12.466, implying 60% upside. The forecast is based on price targets from 10 Wall Street analysts.
Nxera Pharma Co Ltd Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SOLTF's stock price target?
Price Target
12.466
USD
12.466
USD
According to Wall Street analysts, the average 1-year price target for SOLTF is 12.466 USD with a low forecast of 6.672 USD and a high forecast of 31.214 USD.
What is the Revenue forecast for Nxera Pharma Co Ltd?
Projected CAGR
22%
22%
Over the last 6 years, the compound annual growth rate for Revenue has been 20%. The projected CAGR for the next 3 years is 22%.
What is the Gross Profit forecast for Nxera Pharma Co Ltd?
Projected CAGR
24%
24%
Over the last 6 years, the compound annual growth rate for Gross Profit has been 16%. The projected CAGR for the next 3 years is 24%.